Nicorettespray

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nicorettespray

Nicorettespray is a non-prescription medication classified as a Nicotine Replacement Therapy (NRT) agent, primarily used as a support tool for individuals aiming for smoking cessation and managing nicotine addiction. The product delivers the nicotine alkaloid in a controlled, rapid-acting format. It is a specific brand of oromucosal spray developed by McNeil AB, designed for fast relief from withdrawal symptoms.


Quick Facts

Property Description
Active ingredient Nicotine
Form Oromucosal Spray (Buccal Spray)
Pharmacological class Nicotine Replacement Therapy (NRT) agent
Common use Smoking cessation, reduction of cravings
Origin Semi-synthetic (pharmaceutically prepared alkaloid)

What Type of Medicine is Nicorettespray?

Nicorettespray is specifically categorized as an NRT agent, a pharmacological class dedicated to treating tobacco dependence. Its active ingredient, nicotine, is delivered as a single-active ingredient preparation (monotherapy) within an aqueous-alcoholic solution. This class of medication is designed to assist in quitting by stabilizing the body's nicotine levels without the toxic chemicals found in tobacco smoke. NRT in various forms is utilized to increase the likelihood of long-term abstinence compared to no treatment. This medicine is an established method for assisting individuals in achieving successful abstinence.


Nicorettespray’s Unique Oromucosal Form and Purpose

The physical form of the medication is the oromucosal spray (or buccal spray), which is a key differentiating feature of the Nicorettespray brand within the NRT category. This form employs a rapid transmucosal delivery system, ensuring the nicotine is absorbed directly through the highly vascularized lining of the mouth. This delivery method provides a swift onset of action compared to formats like lozenges or chewing gum. The overarching purpose is to provide immediate relief from intense cravings and mitigate the physical symptoms of nicotine withdrawal. The use of NRT helps stabilize physical dependency, allowing the individual to focus on the behavioral changes involved in quitting. This therapy is a recognized strategy for stabilizing dependency during the process of quitting.

Regulatory References

  1. NIH - Nicotine Replacement Therapy
  2. NIH - Treatments for Tobacco Dependence

What side effects are possible with Nicorettespray?

Possible Side Effects and Safety Information

The safety profile for nicotine oromucosal spray is structured around adverse reactions categorized by frequency and the body system affected, based on official regulatory documents. The most frequently reported events are related to the local action of the spray and the systemic effects of nicotine.

Frequency-Classified Adverse Reactions

Adverse reactions are classified into incidence tiers defined by regulatory authorities:

  • Very Common (occurring in 1 in 10 or more users): Hiccups, Throat irritation, Headache, and Nausea.
  • Common (occurring in 1 in 100 to less than 1 in 10 users): Include Dizziness, Dysgeusia (taste disturbance), Dry mouth, Stomatitis, and other Gastrointestinal Disorders (such as vomiting or dyspepsia).
  • Uncommon (occurring in 1 in 1,000 to less than 1 in 100 users): May affect the Cardiovascular system (e.g., palpitations, tachycardia, hypertension) and the Skin (e.g., rash, pruritus, urticaria).

Serious Adverse Reactions and Safety Constraints

While rare, regulatory labeling documents the potential for serious adverse reactions. These include reports of Anaphylactic reaction and Seizures (frequency often categorized as Not Known). A very rare, but documented, serious event is Reversible atrial fibrillation.

Safety constraints require careful consideration in specific populations, as outlined in official labeling. Caution is necessary for patients with certain Cardiovascular Diseases (e.g., recent myocardial infarction, uncontrolled hypertension) and those with Severe Hepatic or Renal Impairment, as nicotine clearance may be affected. The product contains Butylated Hydroxytoluene (BHT), which is documented to potentially cause local irritation to mucous membranes.

Overdose and Emergency Response

The official documentation for nicotine overdose outlines a profile of progressive toxicity. Initial documented manifestations include gastrointestinal symptoms such as nausea, vomiting, diarrhea, abdominal pain, and increased salivation, often accompanied by systemic signs like dizziness, sweating, and rapid heartbeat (tachycardia). As toxicity progresses, more severe effects may occur, involving the central nervous system and cardiovascular system, leading to clinical manifestations such as shallow breathing, hypotension (low blood pressure), slow heartbeat (bradycardia), seizures (convulsions), and coma. Ultimately, regulatory labels caution that severe nicotine exposure can result in respiratory failure or cardiac arrest.

Immediate emergency action is mandatory upon any suspected overdose. The regulatory labeling explicitly states that patients must seek immediate medical attention or contact a Poison Control Center right away. A critical, officially documented risk is the fatal toxicity in children, where doses tolerated by adults can produce severe, life-threatening symptoms in the pediatric population. Suspected nicotine poisoning in a child must be treated immediately as a medical emergency. Management is described as symptomatic and supportive treatment, including the use of activated charcoal to reduce absorption and providing respiratory support for breathing difficulties. Caution is also noted for patients with hepatic or renal impairment, as nicotine clearance may be decreased, potentially increasing toxicity risk.

Therapeutic Uses of Nicorettespray

What Nicorettespray Treats: Main Uses and Benefits

Quick Fact: Relief for Acute Cravings

The product is applied in clinical settings that involve acute or unstable symptom patterns, and is used to provide supportive relief when intense nicotine cravings flare up and threaten the cessation attempt. The supportive action contributes to maintaining functional stability during moments of heightened tension.


The spray is commonly used to provide support for individuals committed to overcoming nicotine addiction and achieving smoking cessation. Its therapeutic role is to help address the physical dependency and manage the immediate, distressing symptomatic burden associated with withdrawal. The medication is relevant for easing symptoms related to heightened physiological activity and managing symptom clusters that may become disruptive, such as anxiety, restlessness, and irritability.

Nicotine Replacement Therapy (NRT) is a treatment used to help people stop smoking by supplying low doses of nicotine, which may assist with cutting down on cravings and easing the symptoms of nicotine withdrawal.

The medication is relevant in conditions characterized by periods of heightened symptoms during the cessation process, often used when symptoms become temporarily overwhelming, and it offers supportive assistance during the challenging initial transition period. This product contributes to easing the overall symptom load, helping to improve day-to-day comfort and maintain patient resolve across the difficult phases of quitting.

Regulatory References

  1. MedlinePlus Medical Encyclopedia

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Nicorettespray — Official Regulatory Information

The eligibility profile for Nicorettespray (Nicotine Oromucosal Spray) is defined by strict regulatory criteria concerning age, cardiovascular health, and certain medical conditions.


Eligibility Scope

Category Regulatory Statement
Populations for whom use is allowed Adults (18 years and over) [standard labeled use]. Adolescents (12 to 18 years) [permitted with limitations].
Populations for whom use is contraindicated Children under 12 years of age. Individuals with documented hypersensitivity to nicotine or any excipient.
Condition-specific eligibility rules Use with caution is required for patients with severe renal impairment, moderate to severe hepatic impairment, uncontrolled hyperthyroidism, or Phaeochromocytoma.

Eligibility-Related Restrictions

  • The product is contraindicated in children under 12 years of age.
  • Use is restricted for dependent smokers with recent, unstable cardiovascular events, including recent myocardial infarction, unstable angina, or severe cardiac arrhythmias.
  • Pregnancy: Use requires a formal risk-benefit assessment led by a healthcare professional.
  • Lactation: Use should be avoided as nicotine is secreted into breast milk, although intermittent forms are generally considered less hazardous than continued smoking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official interaction profile for Nicorettespray, which delivers nicotine as a Nicotine Replacement Therapy (NRT) agent, focuses primarily on two main areas: pharmacodynamic effects with specific co-administered drugs and pharmacokinetic changes resulting from the user's cessation of smoking.

Documented Pharmacodynamic Interaction

Interacting Agent Official Regulatory Description
Adenosine Nicotine may enhance the hemodynamic effects of Adenosine. This includes an officially documented increase in blood pressure, heart rate, and the response to angina-pectoris type chest pain [Source: Regulatory SmPC].

Indirect Pharmacokinetic Effects (Related to Quitting Smoking)

Nicorettespray itself does not induce liver enzymes. However, stopping tobacco smoking reverses the enzyme induction (e.g., CYP1A2) previously caused by chemicals in tobacco smoke. This reversal can lead to increased plasma concentrations of certain co-administered medicinal products whose metabolism is affected by these enzymes, such as Theophylline and Tacrine [Source: Regulatory SmPC].

Population-Specific Interaction Notes

  • Hepatic or Renal Impairment: Caution is required in patients with moderate to severe hepatic impairment or severe renal impairment. The clearance of nicotine may be decreased in these populations, which risks higher systemic exposure [Source: Regulatory FDA Label/SmPC].

No medicinal products are formally labeled as contraindicated combinations with Nicorettespray. There are no mandatory dose-timing separation requirements documented in the regulatory labeling.

Mechanism of Action

Nicotinic Receptor Agonism and Pathway Engagement

The active ingredient, nicotine, operates by acting as a direct agonist at central nicotinic acetylcholine receptors ( nAChRs), primarily engaging the high-affinity alpha4beta2 subtype in the brain. This binding causes the ion channel to open, resulting in neuronal depolarization. The primary mechanistic consequence is the sustained activation of nAChRs that are functionally conditioned by chronic nicotine delivery, preventing the acute neurochemical deficit state.


Modulation of the Dopaminergic System

Activation of these nAChRs initiates a cascade focused on the mesolimbic dopamine pathway. This action modulates signaling within this pathway, leading to the controlled release of dopamine in the Nucleus Accumbens (NAc). This enhancement of dopamine release in the NAc sustains the agonistic effect on the pathway that is conditioned by chronic nicotine intake.


Onset Kinetics and Mechanism Constraint

The rapid absorption provided by the oromucosal spray is mechanically linked to the speed of effect, enabling swift saturation and activation of the CNS nAChRs. However, prolonged or excessive exposure can induce receptor desensitization (tachyphylaxis), a biological constraint where the functional activity of the mechanism is temporarily reduced until the receptor recovers.

Dosage and Administration Information

Principles of Nicorettespray Administration

Nicorettespray is a nicotine oromucosal spray designed for transmucosal delivery, meaning the active ingredient is absorbed directly through the lining of the mouth. This application route dictates specific administration techniques to ensure proper dosage delivery and absorption. The spray is strictly for oromucosal use and must be directed toward the mouth, with users avoiding inhalation or swallowing for a few seconds after application. Additionally, consumption of food or beverages is generally restricted immediately before or during administration to maintain optimal mucosal absorption conditions.


Dosing and Scheduled Tapering

Administration follows a pattern of intermittent use, or it can be based on a fixed schedule, with 1 or 2 sprays used per dose. The use is strictly controlled by rate, with a maximum limit of 4 sprays permitted within any single hour and a total maximum of 64 sprays in a 24-hour period.

Use is structured around a 12-week program comprising three distinct phases to facilitate systematic dose reduction:

  • Weeks 1–6 (Full Dose): Dosing is initiated according to craving frequency, often 1 or 2 sprays every 30 minutes to 1 hour.
  • Weeks 7–9 (Reduction Phase): The daily average dose is gradually reduced, aiming to cut the initial dose by half.
  • Weeks 10–12 (Final Taper): Use is reduced further until the daily dose is decreased to 2 to 4 sprays, leading to treatment cessation.

This structured program defines the typical duration of use, though use beyond six months occurs in specific cases.

Recent Clinical Evidence

Nicorettespray: Recent Clinical Evidence

1. Evidence Supporting Use in Smoking Cessation and Nicotine Addiction

Research exploring methods for quitting smoking includes detailed Systematic Reviews and Meta-analyses of Randomized Controlled Trials (RCTs). These studies were conducted exploring NRT during a quit attempt for smoking cessation and the monitoring of nicotine dependency. The primary focus of this research was studied for measuring outcomes such as the rate of successful quitting and the likelihood of long-term abstinence.

Studies exploring how symptoms change over time reported measurements of blood nicotine levels in participants compared to control groups that received no active treatment. These comprehensive analyses described a statistical pattern where outcomes related to long-term abstinence were observed more frequently in the NRT group compared to control groups. Research describes the aim of supporting the physical dependency aspect and explores the ability of participants to focus on behavioral changes.

2. Evidence Supporting Relief of Acute Cravings and Withdrawal Symptoms

The specific physical form of Nicorettespray—an oromucosal spray—was evaluated in Pharmacological Studies and focused Clinical Trials. Research examined its performance relevant in trials assessing short-term or episodic symptom patterns during a quit attempt. These studies focused on outcomes such as the onset of action and tracked the change in the intensity of intense nicotine cravings.

Findings related to the oromucosal form indicate patterns of rapid delivery. Research explored short-term symptom changes and described that the spray was studied during periods of increased symptom activity and research examined outcomes related to relief of symptoms when symptoms became heightened.

3. What Is Still Unclear or Unstudied About Nicorettespray Evidence

The evidence highlights what is known, but also what is still uncertain. The primary uncertainty lies in the fact that, because NRT addresses only the physical dependency, other factors are also explored in research related to successful quitting. Furthermore, data for certain groups remain insufficient, meaning the certainty remains low regarding the response patterns and longer-term outcomes for populations such as adolescents or those with multiple coexisting conditions.

Key Studies & References MedlinePlus Medical Encyclopedia - Nicotine Replacement Therapy

Frequently Asked Questions (FAQ)

Common questions about Nicorettespray (FAQ)

Q: How does Nicorettespray compare to nicotine patches?

The primary difference is the delivery method. Nicorettespray is a fast-acting nicotine replacement therapy (NRT) that delivers nicotine through the mouth, with levels peaking quickly within minutes. Nicotine patches, according to clinical guidance, provide a slow and steady dose of nicotine absorbed through the skin over several hours.


Q: What is the difference between the spray and nicotine gum?

Both the spray and nicotine gum are considered fast-acting NRT options. However, official studies indicate that the spray allows for more rapid absorption and a faster onset of effect, which studies associate with the management of cravings, compared to gum or lozenges.


Q: How quickly is Nicorettespray supposed to work?

The oromucosal form allows for rapid absorption through the lining of the mouth. Clinical data shows that peak nicotine levels are typically reached within about 16 minutes after administration. This swift action is associated with a quick onset of action, which can aid in the management of acute cravings.


Q: What should I expect immediately after using the spray?

It is very common to experience local reactions immediately after application, according to official side effect reports. These may include temporary throat irritation, hiccups, or a burning sensation in the mouth. Nausea is also a frequently reported effect.


Q: Are there any specific foods or drinks that should be avoided when using Nicorettespray?

The administration guidance specifies that consumption of food or beverages should be avoided when the spray is administered, or shortly beforehand. This is because eating or drinking may reduce the nicotine absorbed through the oral lining.


Q: What are the ingredients in Nicorettespray besides nicotine?

Besides the active ingredient, nicotine, the spray contains a list of inactive ingredients, or excipients, to stabilize the product. Key excipients include a small amount of ethanol (alcohol), propylene glycol (E1520), and butylated hydroxytoluene (BHT). The official labeling contains the complete list of ingredients.


Q: Can using Nicorettespray impact my ability to drive or operate machinery?

Official product information includes a section on the spray's effect on the ability to drive and use machines. Since common side effects can include dizziness, caution is advised regarding these activities.


Q: Do regulatory bodies consider Nicorettespray a safe choice for nicotine replacement?

Regulatory bodies and health authorities clinically recognize Nicotine Replacement Therapy (NRT) as an established treatment option with demonstrated efficacy for tobacco dependence. This determination is based on the regulatory assessment that the product’s benefits are understood to outweigh the risks.


Q: Is the nicotine in Nicorettespray different from the nicotine in cigarettes?

The active ingredient in the spray is the same nicotine alkaloid found in tobacco. The key difference is that Nicorettespray delivers this nicotine without the thousands of toxic chemicals and carcinogens present in tobacco smoke.


Q: How long does the effect of one dose of Nicorettespray typically last?

The effect of a single dose is not stated in hours, but the official dosing structure gives an indication. The official documents describe a structured use pattern where administration can occur at intervals, such as every 30 minutes to one hour, based on the user's need to control cravings.


Q: Is Nicorettespray an option for someone who only smokes occasionally?

The product is officially indicated for the treatment of established tobacco dependence and for the relief of cravings and withdrawal symptoms associated with quitting. Its primary use is framed around managing physical dependency.


Q: What is the general safety classification of Nicorettespray?

Nicorettespray is classified pharmacologically as a Nicotine Replacement Therapy (NRT) agent, which is a medication category dedicated to treating tobacco dependence. It is listed on the World Health Organization’s Model List of Essential Medicines.


Q: Is there a strong taste or smell associated with Nicorettespray?

The solution is officially described in the product information as having a specific scent and taste, depending on the flavor selected. This is by design, as inactive ingredients are used to enhance palatability and aid in patient acceptance.


Q: Is it normal to feel a burning sensation in the mouth after using it?

A burning sensation may occur as a common local reaction. Official side effect reports list throat irritation and stomatitis (inflammation of the mouth) as frequent adverse effects, and this local physical reaction may feel like a temporary burning sensation.


Q: What should I do if I accidentally swallow the spray?

Official product warnings indicate that swallowing large amounts can lead to nicotine poisoning, which is a serious risk, especially for children. Regulatory guidance advises seeking immediate medical assistance or contacting a Poison Control Center if accidental swallowing occurs.


Q: What if the spray causes me to cough?

The most common side effect is throat irritation, which may temporarily cause coughing. This is often a temporary physical reaction to the administration of the spray to the back of the throat/mouth area.


Q: What does official guidance say about using the spray with alcohol?

Official product information states that the spray contains a very small amount of ethanol (alcohol) as an inactive ingredient. The quantity per spray is equivalent to less than 2 mL of beer or 1 mL of wine and is explicitly stated to not have any noticeable effects.


Q: What is the likelihood of developing a dependence on Nicorettespray?

Regulatory documents state that dependence on nicotine replacement products is considered rare compared to the dependence caused by tobacco smoking. The treatment is generally recognized as a treatment option considered less prone to dependence than tobacco smoking itself.


Q: What is the role of the other ingredients (like flavorings) in the spray?

Inactive ingredients (excipients) are included to ensure that the product is stable, functions correctly, and is accepted by the user (palatability). For example, Butylated Hydroxytoluene (BHT) is included in the solution, which may cause local irritation in some individuals.


Q: Does the strength of the spray relate to the amount of cigarettes I smoke?

Nicorettespray is a fixed-strength product (1 mg per spray). However, official NRT guidance indicates that a higher overall dosing intensity may be considered for individuals with a high nicotine dependence (such as those smoking over 20 cigarettes per day).


Q: What are the official warnings about using Nicorettespray if I have diabetes?

Official warnings state that for patients with diabetes mellitus, the cessation of smoking may require an assessment of the user’s insulin doses. This is due to the metabolic changes that occur after nicotine cessation, which can impact blood sugar levels.


Q: Is there information on how Nicorettespray might affect my sleep?

Sleep disturbance is not listed as a primary side effect in official documents. However, common effects on the nervous system, such as dizziness and headache, may indirectly affect the quality of sleep in some individuals.


Q: What if I forget to use the spray when I typically would?

Since the spray is an on-demand medication, the official instructions are structured around using it when the urge to smoke occurs. If a typical usage time is missed, the product is designed to be used when the urge to smoke next occurs.

How should Nicorettespray be stored and disposed of?

The official regulatory documents define mandatory requirements for the storage, protection, and disposal of Nicorettespray (nicotine oromucosal spray) to ensure product stability and safety.

Storage Requirement Official Condition
Temperature Store at a temperature no higher than 30 C; do not freeze the product.
Protection Store in the original container with the dispenser cap firmly closed to protect it from light and moisture.
Child Safety Must be stored out of the sight and reach of children due to the toxicity of concentrated nicotine.

For disposal, the product must not be discarded via household waste or wastewater. Unused medicine and the empty dispenser should be returned to the pharmacist for disposal in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nicorettespray found in:

A-Z Index: